Items per page
1 - 167 of 167
Title Published in Access level OA Policy Year Views Downloads
Autoimmunity in MASLD : Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptorsEuropean journal of clinical investigation
accessLevelPublic
2025 66 111
Prise en charge de la dyslipidémie diabétiqueRevue médicale suisse
accessLevelRestricted
2025 4 0
Autoantibodies against apolipoprotein A-1 and cadmium : possible links tocardiovascular and liver diseases across multiple modelsESC (European Society of Cardiology) Congress 2025
2025 5 0
Autoantibodies against apolipoprotein A-1 and cadmium : Possible links tocardiovascular and liver diseases across multiple models93rd EAS (European Atherosclerosis Society) Congress
2025 4 0
Analogues du GLP-1 dans le traitement du diabète de type 2 et de l’obésité : la panacée ?Revue médicale suisse
accessLevelRestricted
2025 5 0
Multi-omics correlates of insulin resistance and circadian parameters mapped directly from human serumEJN. European journal of neuroscience
accessLevelPublic
2024 76 129
Alterations of lipid homeostasis in morbid obese patients are partly reversed by bariatric surgeryiScience
accessLevelPublic
2024 82 52
S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effectsScience advances
accessLevelPublic
2024 330 136
Linking antibody against apolipoprotein A-1 to nonalcoholic steatohepatitis in mice92nd EAS (European Atherosclerosis Society) Congress
2024 4 0
Corticosteroid therapy in older adults with cancer : Expert recommendations from a task force of the International Society of Geriatric OncologyJournal of geriatric oncology
accessLevelRestricted
2024 34 0
Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associatedsteatohepatitis in miceESC (Europan Society of Cardiology) Congress 2024
2024 2 0
Geospatial clustering of auto-antibodies against apolipoprotein A-1, heavy metals,cardiovascular and liver diseases in the general populationESC (Europan Society of Cardiology) Congress 2024
2024 5 0
Diabétologie : ce qui a changé en 2023Revue médicale suisse
accessLevelRestricted
2024 102 5
Lysophosphatidylinositols Are Upregulated After Human β-Cell Loss and Potentiate Insulin ReleaseDiabetes
accessLevelRestricted
2024 363 3
N ADPH oxidases in healthy white adipose tissue and in obesity : function, regulation, and clinical implicationsObesity
accessLevelPublic
2024 103 72
Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in MiceInternational journal of molecular sciences
accessLevelPublic
2024 118 93
Gastroparésie diabétique et diabète de type 1Revue médicale suisse
accessLevelRestricted
2024 117 2
Langerhans Cell Histiocytosis of the Suprasellar Region : Diagnosis on Thyroid CytologyEuropean thyroid journal
accessLevelPublic
2024 115 128
Geospatial clustering of auto-antibodies against apolipoprotein A-1, heavy metals, cardiovascular and liver diseases in the general population92nd EAS (European Atherosclerosis Society) Congress
2024 6 0
Gynécologie-obstétrique. Prise en charge et dépistage du diabète gestationnel : ce qui a changé en 2023Revue médicale suisse
accessLevelRestricted
2024 204 2
Toutes nos différences…Revue médicale suisse
accessLevelRestricted
2024 62 2
Interprofessional diabetes and foot management in low-and middle-income countries or humanitarian crises contextsInternational Diabetes Federation (IDF) virtual congress
accessLevelPublic
2023 55 77
Pied diabétique : une prise en charge complexe et multidisciplinaireRevue médicale suisse
accessLevelPublic
2023 125 17
Nonalcoholic fatty liver disease in type 1 diabetes : where are we?Polskie Archiwum Medycyny Wewnętrznej
accessLevelPublic
2023 88 55
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetesDiabetes & metabolism
accessLevelPublic
2023 130 355
A global research priority agenda to advance public health responses to fatty liver diseaseJournal of hepatology
accessLevelPublic
2023 119 225
Diabétologie : ce qui a changé en 2022Revue médicale suisse
accessLevelPublic
2023 131 9
Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver DiseaseInternational journal of molecular sciences
accessLevelPublic
2023 125 82
Circadian organization of lipid landscape is perturbed in type 2 diabetic patientsCell reports. Medicine
accessLevelPublic
2023 265 135
Stéatopathie non alcoolique (NAFLD) et diabète : le mauvais mariageRevue médicale suisse
accessLevelPublic
2023 126 26
Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testingEuropean thyroid journal
accessLevelPublic
2023 209 200
Traitement du diabète de type 2 : et si nous revenions à l’essentiel ?Revue médicale suisse
accessLevelPublic
2023 91 9
A multi–society Delphi consensus statement on new fatty liver disease nomenclatureJournal of hepatology
accessLevelPublic
2023 129 490
The impact of transsphenoidal surgery on pituitary function in patients with non-functioning macroadenomasEndocrine
accessLevelPublic
2023 135 163
Neuropathie diabétique : mise au pointRevue Médicale Suisse
accessLevelPublic
2022 162 628
Effectiveness of Therapeutic Patient Education Interventions in Obesity and Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsNutrients
accessLevelPublic
2022 185 202
NAFLD: From Mechanisms to Therapeutic ApproachesBiomedicines
accessLevelPublic
2022 149 168
Allergie à l’insuline : comment faire ?Revue médicale suisse
accessLevelPublic
2022 137 190
Non-alcoholic fatty liver disease in type 1 diabetes: prevalence and pathophysiologyFrontiers in endocrinology
accessLevelPublic
2022 154 250
Diabète pancréatopriveRevue médicale suisse
accessLevelPublic
2022 533 147
Pheochromocytoma presented by Takotsubo, unmasked by accumulation of paroxetine, in a cytochrome poor metabolizer patient: A case reportThérapie
accessLevelRestricted
2022 365 1
Interleukin-18 in metabolism: from mice physiology to human diseasesFrontiers in endocrinology
accessLevelPublic
2022 180 244
Canakinumab in patients with COVID-19 and type 2 diabetes – a multicentre, randomised, double-blind, placebo-controlled trialEClinicalMedicine
accessLevelPublic
2022 129 96
Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesityEndocrine connections
accessLevelPublic
2022 229 145
(650) Efficacy of therapeutic patient education interventions in metabolic disorders: a systematic review and meta-analysis58th EASD Annual Meeting of the European Association for the Study of Diabetes
2022 245 7
Circulating 1,5-anhydroglucitol as a biomarker of ß-cell mass independent of a diabetes phenotype in human subjectsJournal of clinical endocrinology & metabolism
accessLevelRestricted
2022 412 2
Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 daysAnnals of surgery
accessLevelPublic
2022 250 338
NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic OutlookAntioxidants
accessLevelPublic
2022 276 338
Dernières recommandations européennes sur les dyslipidémiesRevue médicale suisse
accessLevelPublic
2022 379 647
Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesisNature communications
accessLevelPublic
2022 375 100
Diabète : la pandémie comme révélateur de nos succès/nos faillesRevue médicale suisse
accessLevelPublic
2022 52 21
DiabétologieRevue médicale suisse
accessLevelPublic
2022 90 57
Hépatopathie et diabète de type 2Leading Opinions. Médecine Interne
accessLevelRestricted
2022 118 0
Tratamiento podológico del pie diabéticoEncyclopédie médico-chirurgicale. Podología
accessLevelRestricted
2022 114 0
Systematic Review and Meta-Analysis of the Usefulness of Epicardial Fat Thickness as a Non-Invasive Marker of the Presence and Severity of Nonalcoholic Fatty Liver DiseaseBiomedicines
accessLevelPublic
2022 153 111
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetesCardiovascular diabetology
accessLevelPublic
2022 111 272
Prise en charge podologique du pied diabétiqueEncyclopédie médico-chirurgicale. Podologie
accessLevelRestricted
2022 139 0
Growth differentiation factor-15 prevents glucotoxicity and connexin-36 downregulation in pancreatic beta-cellsMolecular and cellular endocrinology
accessLevelPublic
2022 103 131
Le diabète : une pandémie oubliée ?Revue médicale suisse
accessLevelPublic
2021 123 236
Inhibiteurs du SGLT2 : que des bénéfices?Revue médicale suisse
accessLevelPublic
2021 377 250
Is routine measurement of the serum C-reactive protein level helpful during antibiotic therapy for diabetic foot infection?Diabetes, Obesity and Metabolism
accessLevelRestricted
2021 188 0
Diabète de type MODY : une entité souvent méconnueRevue médicale suisse
accessLevelPublic
2021 177 133
Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patientsActa Physiologica
accessLevelRestricted
2021 397 3
DiabétologieRevue médicale suisse
accessLevelRestricted
2021 203 2
Pathophysiology of NASH in endocrine diseasesEndocrine Connections
accessLevelPublic
2021 220 168
Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLDInternational journal of molecular sciences
accessLevelPublic
2021 153 187
DiabétologieRevue médicale suisse
accessLevelRestricted
2020 242 2
Diabète: et si on se mettait à la place du patient?Revue médicale suisse
accessLevelRestricted
2020 245 0
Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world settingDiabetes, Obesity and Metabolism
accessLevelPublic
2020 486 326
Thirteen-year trends in the prevalence of diabetes according to socioeconomic condition and cardiovascular risk factors in a swiss populationBMJ Open Diabetes Res Care
accessLevelPublic
2020 336 162
Real-World Effectiveness of Insulin Glargine 300 Initiation in SwitzerlandDiabetes, Metabolic Syndrome and Obesity
accessLevelPublic
2020 300 177
La NASH: une complication moins connue mais importante du diabèteRevue médicale suisse
accessLevelRestricted
2020 356 0
The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient dietTranslational Research
accessLevelPublic
2020 557 288
Quelle place pour les inhibiteurs de la DPP-4 en 2020?Revue médicale suisse
accessLevelRestricted
2020 547 0
Ulcère du pied chez un patient avec un diabète : quelle prise en charge médico-chirurgicale ?Revue médicale suisse
accessLevelRestricted
2020 331 1
Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case reportBMC Endocrine Disorders
accessLevelPublic
2020 206 128
Diabète après transplantation rénale : mise au pointRevue médicale suisse
accessLevelRestricted
2020 352 4
Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trialClinical Infectious Diseases
accessLevelPublic
2020 344 779
Insuffisance rénale chronique et nouveaux traitements antidiabétiques : tour d'horizon en 2019Revue médicale suisse
accessLevelPublic
2019 674 274
Thirteen-year trends in the prevalence of diabetes in an urban region of Switzerland: a population-based studyDiabetic Medicine
accessLevelRestricted
2019 262 0
Salivary cortisol is not associated with incident insulin resistance or type 2 diabetes mellitusEndocrine Connections
accessLevelPublic
2019 317 109
Faut-il prescrire plus d'inhibiteurs SGLT-2 ?Revue médicale suisse
accessLevelPublic
2019 302 133
[News in diabetology 2018]Revue médicale suisse
accessLevelPublic
2019 273 84
Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolismScientific Reports
accessLevelPublic
2019 468 127
Nonalcoholic fatty liver disease burdenSwiss Medical Weekly
accessLevelPublic
2019 312 175
Prise en charge de la dyslipidémie chez les patients avec un diabète de type 1Revue médicale suisse
accessLevelPublic
2018 515 48
DiabétologieRevue médicale suisse
accessLevelPublic
2018 416 52
Observance thérapeutique et empilage médicamenteuxRevue médicale suisse
accessLevelPublic
2018 367 171
Fibroblast Growth Factor 15/19 - From Basic Functions to Therapeutic PerspectivesEndocrine Reviews
accessLevelPublic
2018 497 162
Transition optimale hôpital-domicile d'un patient diabétique de type 2 : quelques outilsRevue médicale suisse
accessLevelPublic
2018 563 137
Consequences of the Adoption of the IADPSG versus Carpenter and Coustan Criteria to Diagnose Gestational Diabetes: A Before-After ComparisonExperimental and Clinical Endocrinology and Diabetes
accessLevelRestricted
2018 513 2
An Overview on Diabetic Foot Infections, including Issues Related to Associated Pain, Hyperglycemia and Limb IschemiaCurrent Pharmaceutical Design
accessLevelRestricted
2018 488 1
Diabète prégestationnel : une entité de plus en plus fréquenteRevue médicale suisse
accessLevelPublic
2018 506 167
Diabète de type 1, activité physique et nouvelles technologiesRevue médicale suisse
accessLevelPublic
2018 766 364
β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissueJCI insight
accessLevelPublic
2017 583 277
Utilité de la mesure en continu de la glycémie chez les patients diabétiques de type 2Revue médicale suisse
accessLevelRestricted
2017 389 0
Treatment challenges in type 1 diabetes after roux-en-Y gastric bypassSwiss Medical Weekly
accessLevelPublic
2017 410 200
AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient miceMolecular Metabolism
accessLevelRestricted
2017 414 0
Diabète sucré secondaire à une endocrinopathie : quand y penser ?Revue médicale suisse
accessLevelPublic
2017 547 987
Diètes cétogènes : la solution miracle ?Revue médicale suisse
accessLevelPublic
2017 1,333 635
Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human StudiesNutrients
accessLevelRestricted
2017 467 0
Translational Aspects of Diet and Non-Alcoholic Fatty Liver DiseaseNutrients
accessLevelRestricted
2017 489 0
Traitement du diabète: quand faire appel au diabétologue?Revue médicale suisse
accessLevelPublic
2017 369 193
Grip strength is not associated with incident type 2 diabetes mellitus in healthy adults: The CoLaus studyDiabetes Research and Clinical Practice
accessLevelRestricted
2017 471 0
DiabétologieRevue médicale suisse
accessLevelPublic
2017 406 105
GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on boneMolecular Nutrition and Food Research
accessLevelPublic
2017 562 394
Effects of Antidiabetic Drugs on Gut Microbiota CompositionGenes
accessLevelRestricted
2017 440 0
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous PemphigoidDermatology
accessLevelRestricted
2017 425 0
Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examplesJournal of Immunological Methods
accessLevelRestricted
2017 397 1
Place des nouveaux antidiabétiques dans la population gériatriqueRevue médicale suisse
accessLevelRestricted
2016 417 1
Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistanceFASEB Journal
accessLevelRestricted
2016 369 0
Fasting glycaemia to simplify screening for gestational diabetesBJOG: an International Journal of Obstetrics and Gynaecology
accessLevelRestricted
2016 591 1
Diabète gestationnel – quelles sont les approches non médicales ?Revue médicale suisse
accessLevelRestricted
2016 420 1
Comment faire pour prévenir le diabète de type 2 en Suisse?Revue médicale suisse
accessLevelRestricted
2016 419 2
Leptin as a Potential Regulator of FGF21Cellular physiology and biochemistry
accessLevelPublic
2016 626 231
Preserving of Postnatal Leptin Signaling in Obesity-Resistant Lou/C Rats following a Perinatal High-Fat DietPloS one
accessLevelPublic
2016 518 199
Sécurité cardiovasculaire des antidiabétiquesRevue médicale suisse
accessLevelRestricted
2016 427 0
DiabétologieRevue médicale suisse
accessLevelRestricted
2016 373 0
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell ProtectionArteriosclerosis, Thrombosis, and Vascular Biology
accessLevelRestricted
2016 615 1
Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus studyCardiovascular Diabetology
accessLevelPublic
2016 535 220
Endocrine causes of nonalcoholic fatty liver diseaseWorld Journal of Gastroenterology
accessLevelRestricted
2015 480 0
Free Fatty Acids Impair FGF21 Action in HepG2 CellsCellular physiology and biochemistry
accessLevelPublic
2015 559 330
Metformine : nouvelles données pour une ancienne moléculeRevue médicale suisse
accessLevelRestricted
2015 443 2
Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21Journal of Endocrinology
accessLevelPublic
2015 818 381
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?Molecular and Cellular Endocrinology
accessLevelPublic
2015 539 1,551
Classification du diabète : vers une hétérogénéité croissanteRevue médicale suisse
accessLevelRestricted
2015 394 0
Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose TissuePloS one
accessLevelPublic
2015 622 308
Le diabète en 2015 : en augmentation constante, mais avec une offre thérapeutique qui s'élargitRevue médicale suisse
accessLevelRestricted
2015 403 1
Prise en charge des facteurs de risque des maladies cardiovasculaires : qu'est-ce qui a vraiment changé en 15 ans ?Revue médicale suisse
accessLevelRestricted
2015 426 1
Edulcorants artificiels et diabète : faux amis ?Revue médicale suisse
accessLevelRestricted
2015 396 0
ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid contentJournal of Lipid Research
accessLevelRestricted
2015 468 0
Serum Vitamin D Concentrations Are Not Associated with Insulin Resistance in Swiss AdultsThe Journal of nutrition
accessLevelRestricted
2015 539 0
Transition en diabétologieRevue médicale suisse
accessLevelRestricted
2015 558 1
Diets and nonalcoholic fatty liver disease: The good and the badClinical nutrition
accessLevelRestricted
2014 673 1
Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 DiabetesJournal of general internal medicine
accessLevelRestricted
2014 590 1
Maladies hépatiques chroniques et diabèteRevue médicale suisse
accessLevelRestricted
2014 489 0
Traitement combiné d'insuline et d'analogue du GLP-1 : qu'en attendre ?Revue médicale suisse
accessLevelRestricted
2014 573 0
Ostα-/- mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivityAmerican Journal of Physiology. Gastrointestinal and Liver Physiology
accessLevelRestricted
2014 455 0
Muscle-specific activation of Ca(2+)/calmodulin-dependent protein kinase IV increases whole-body insulin action in miceDiabetologia
accessLevelRestricted
2014 502 0
Cellular mechanisms by which FGF21 improves insulin sensitivity in male miceEndocrinology
accessLevelRestricted
2013 759 0
CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistanceProceedings of the National Academy of Sciences
accessLevelRestricted
2013 502 0
Increased FGF21 plasma levels in humans with sepsis and SIRSEndocrine connections
accessLevelPublic
2013 626 263
Non-alcoholic fatty liver disease and insulin resistance: from bench to bedsideDiabetes & metabolism
accessLevelRestricted
2013 633 0
Enhanced fasting glucose turnover in mice with disrupted action of TUG protein in skeletal muscleJournal of Biological Chemistry
accessLevelRestricted
2013 504 0
Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistanceEndocrinology
accessLevelRestricted
2013 462 0
Sport et diabète de type 1Revue médicale suisse
2013 668 0
Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistanceJournal of Endocrinology
accessLevelRestricted
2013 671 0
Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistanceEndocrinology
accessLevelRestricted
2012 459 0
Development of insulin resistance in mice lacking PGC-1α in adipose tissuesProceedings of the National Academy of Sciences
accessLevelRestricted
2012 417 0
Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out miceJournal of Biological Chemistry
accessLevelRestricted
2012 436 0
Sommeil et diabèteRevue médicale suisse
accessLevelRestricted
2012 508 0
Diabète et stéatose hépatique non alcooliqueRevue médicale suisse
accessLevelRestricted
2012 626 0
Weight and mortality in adults with diabetesJAMA
accessLevelRestricted
2012 593 0
Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patientsActa Diabetologica
accessLevelRestricted
2012 436 0
Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in miceCell Metabolism
accessLevelRestricted
2011 455 0
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistanceHepatology
accessLevelRestricted
2011 445 1
Pregnancy does not accelerate corticotroph tumor progression in Nelson's syndromeJournal of Clinical Endocrinology and Metabolism
accessLevelRestricted
2011 477 0
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell functionDiabetes
accessLevelRestricted
2011 397 0
Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2Proceedings of the National Academy of Sciences
accessLevelRestricted
2011 501 0
Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistanceCell Metabolism
accessLevelRestricted
2010 467 0
A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gainAmerican Journal of Physiology. Endocrinology and Metabolism
accessLevelRestricted
2010 443 0
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individualsDiabetologia
accessLevelRestricted
2010 639 0
Myeloperoxidase and paraoxonase-1 in type 2 diabetic patientsNMCD. Nutrition Metabolism and Cardiovascular Diseases
accessLevelRestricted
2009 639 0
Mucocutaneous papillomatous papules in Cowden's syndromeClinical and experimental dermatology
accessLevelRestricted
2008 550 0
Assessment of hepatic glucose metabolism by indirect calorimetry in combination with a non-invasive technique using naturally enriched 13C glucose in healthy children and adolescentsHormone Research
accessLevelRestricted
2004 427 0
Metabolism of oral glucose in children born small for gestational age: evidence for an impaired whole body glucose oxidationMetabolism
accessLevelRestricted
2004 433 0
Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1The Journal of clinical endocrinology and metabolism
accessLevelRestricted
2003 637 0
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack